BillionToOne projects 2026 revenue of $415-430 million

BillionToOne Inc. (NASDAQ: BLLN) provided financial guidance for 2026 and reiterated its 2025 revenue outlook. The molecular diagnostics company expects 2026 revenue of $415 million to $430 million, representing growth of 40% to 45% compared to the midpoint of its 2025 guidance range.

The company maintained its 2025 revenue guidance of $293 million to $299 million with positive GAAP operating income. BillionToOne also projects positive GAAP operating income for 2026.

"As we look ahead to 2026, we are excited by the opportunity to further scale our differentiated platform built on innovative science and disciplined execution," said Dr. Oguzhan Atay, co-founder and CEO of BillionToOne.

The Menlo Park, California-based company develops molecular diagnostic tests using its Quantitative Counting Templates molecular counting platform. The technology is designed to count DNA molecules at the single-molecule level.

The guidance was provided in a press release statement issued by the company.

You May Also Be Interested In

• FOMC minutes from July 28-29th meeting
• Stripe agrees to acquire AI model routing platform OpenRouter
• Wolverine World Wide (WWW) PT Raised to $20 at Williams Trading